Shares of Intra-Cellular Therapies ITCI remained unaffected after the company reported Q3 results.
Quarterly Results
Earnings per share decreased 25.40% year over year to ($0.79), which beat the estimate of ($1.00).
Revenue of $7,369,000 higher by 0.00% year over year, which beat the estimate of $5,860,000.
Looking Ahead
Intra-Cellular Therapies hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Nov 09, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/h8856x5f
Technicals
Company's 52-week high was at $43.56
52-week low: $8.51
Price action over last quarter: Up 29.21%
Company Overview
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
